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patient hospital records analysis for the years 1998–2000,
validated by expert panel opinion. The consensus method
used was a modiﬁed form of the Rand Version of the
Nominal Group Technique. For severity stages I/II and III
analysis was conducted for subgroups of patients accord-
ing to menopausal and estrogen/progesterone receptor
status. Results were reported in the form of “decision
analysis trees” for each patient group. Probability distri-
butions were based on the frequency of usage of each
treatment pathway. For Stage IV patients, analysis was
conducted regardless of menopausal and ER/PR status.
Clinical practice was reported at sequential lines of
patient management in frequency tables depicting usage
ratios of each therapeutic pathway. RESULTS: Treatment
appears more standardized for disease stages I, II, III. The
most frequently used therapy is surgery followed by
radiotherapy and adjuvant therapy. Stage III patients 
are more likely to receive neo-adjuvant therapy. ER/PR
status determines the choice of adjuvant therapy, as
patients with positive receptors are most likely to re-
ceive endocrine therapy alone or in combination with
chemotherapy. In Stage IV, observed treatment pathways
present varying sequential usage across patients, with sys-
temic chemotherapy, endocrine therapy and radiotherapy
as the most frequent clinical options. CONCLUSIONS:
The model seems a feasible approach in depicting current
clinical practice in Greece. It can be used as tool for clin-
icians and decision makers for monitoring health care
costs, estimating cost of illness, and evaluating the intro-
duction of new therapies in the management of Breast
Cancer patients in Greece.
CANCER—Cost Studies
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OBJECTIVE: To estimate the difference in total direct
cost between daily ﬁlgrastim injections versus a single
once-per-cycle pegﬁlgrastim injection over four cycles 
in France and Germany. METHOD: The perspective of
analysis was that of the national health care services. A
Markov model was used to estimate the total direct costs
for neutropenia management over four chemotherapy
cycles. Total costs included drug administration cost,
drug acquisition cost, patient monitoring cost and febrile
neutropenia (FN) management cost. Clinical data were
obtained from a meta-analysis of two pivotal, randomised
double-blind clinical trials comparing ﬁlgrastim and peg-
ﬁlgrastim [Siena S et al. Oncol Rep 2003;10:715–24.].
The drug administration cost and patient monitoring cost
were estimated using a time and motion method. The per
cycle drug administration cost for ﬁlgrastim and pegﬁl-
grastim was €155 and €14, respectively, in France and
€530 and €67 in Germany. The per cycle drug acquisition
cost for ﬁlgrastim and pegﬁlgrastim was assumed equal
in both countries. In France, the per cycle monitoring cost
for ﬁlgrastim and pegﬁlgrastim was €43 and €22, com-
pared to €31 and €15 in Germany. The cost for manag-
ing FN in France was €2439 per episode and €1816 in
Germany. RESULTS: In both countries, a once-per-cycle
pegﬁlgrastim injection was less expensive than daily injec-
tions of ﬁlgrastim. The mean total cost for neutropenia
management with ﬁlgrastim and pegﬁlgrastim was, re-
spectively, €6056 and €5213 over 4 chemotherapy cycles
in France, and €6449 and €4850 in Germany. The dif-
ference was mainly due to a lower FN rate in the pegﬁl-
grastim group [11% vs. 19% in the ﬁlgrastim arm (p <
0.05)] and a lower drug administration cost. CONCLU-
SION: Compared to ﬁlgrastim, the use of pegﬁlgrastim
reduced the total cost for neutropenia management in
France and Germany.
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OBJECTIVES: The objectives of this retrospective data-
base study were to estimate the treatment costs for bone
fractures in older women (aged 65 years and older) who
have early breast cancer and to compare those costs with
the treatment costs for bone fractures incurred by older
women who do not have breast cancer. METHODS:
Direct costs for bone fractures in early breast cancer
patients were evaluated using the Medicare 5% sample
data (1997–1998), including the estimation of “medical
treatment costs for bone fracture,” “excess treatment
costs for bone fracture,” and “excess LTC costs for bone
fracture.” Inpatient costs, medical treatment costs, and
LTC admission rates were compared between a cohort of
women with early breast cancer and bone fracture and an
age-matched cohort of normal women with bone frac-
ture, stratiﬁed by age group, status of hospitalization for
bone fracture, and type of bone fracture. RESULTS: For
older women with early breast cancer, the “direct cost for
bone fracture” was estimated to be about $45,579, 57%
of which is for treatment costs of the bone fracture
(including 32% of inpatient hospital costs and 25% of
non-inpatient hospital costs), 24% for other excess treat-
ment costs, and 18% for excess long-term care costs.
CONCLUSIONS: This study represents the ﬁrst research
on the costs of bone fracture in older women with early
breast cancer. It shows that bone fracture is costly in this
733Abstracts
group. However, there is no signiﬁcant difference between
the costs of bone fracture in older women with early
breast cancer and older women who do not have breast
cancer.
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OBJECTIVES: The decision to decide for operating liver
metastases in colorectal cancer (CRC) patients depends
largely on the performance of imaging techniques. A more
sensitive and speciﬁc test is only of value when it induces
a change in therapeutical decisions. This study aimed at
analysing the health economic impact of Resovist®, a
superparamagnetic iron oxide used in magnetic resonance
imaging (MRI) for the diagnosis of hepatic CRC metas-
tases. The selected setting was Belgium. METHODS: A
medical decision tree model simulating a patient’s evolu-
tion applying a 5-year time horizon was developed using
2 scenarios; 1) current diagnostic algorithms; and 2)
Resovist® added to current algorithms). Clinical data
reveal that, in comparison to current diagnosis Resovist®
offers an increased sensitivity (95.4 vs. 74.3 %) and a
moderately increased speciﬁcity (89.4 vs. 86.2 %), and
such an improved test performance would change medical
management in about 30% of patients. A Delphi panel
with 16 members indicated that this change in practice
would be in 29 % from no operation to operation and in
71% from operation to no operation. The Delphi panel
also provided medical resource use data. Costs of medical
resources were obtained from the public health insurance.
Life expectancy in function of chosen medical action was
obtained from epidemiological literature. RESULTS:
Resovist® increased costs with €655.4, and adds 1.32
months to life resulting in a cost-effectiveness = €5958 per
Life Year Gained, which means good value for money.
Sensitivity analysis (20% up and down) on performance
of the diagnostic tool, cost of treatment options and
change in medical practice showed robustness of the con-
clusions with a maximal range from €3527 to €10,032.
CONCLUSION: This medical decision tree approach
showed that Resovist® has the potential to improve
medical management and outcomes at a very acceptable
ratio between costs and effects.
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OBJECTIVES: Since May 2001, vinorelbine has been
available to be administered in oral form at home in the
treatment of non-small cell lung cancer. Its efﬁcacy is
similar to that of IV vinorelbine, gastro-intestinal toxic-
ity is more frequent. The periodicity of the treatment
follow up in a hospital environment is poorly deﬁned.
The aim of this study is to establish the regimen, which
minimises costs whilst ensuring patient safety. ME-
THODS: A model was constructed in order to follow 
the repercussions of attending hospital every 3, 6, or 9
weeks compared to purely outpatient, weekly manage-
ment. The corresponding costs were compared to those
of conventional treatments used in the indication: 
gemcitabine, docetaxel and paclitaxel. Costs were esti-
mated from the society perspective. For hospital courses,
the DRG costs were adjusted by replacing the drugs com-
ponent by the actual cost of the substances. For the oral
form, primary care costs are allocated values using the
price of oral form and the primary care visit or an hos-
pital specialist consultation. RESULTS: For equivalent
therapeutic efﬁcacy, oral vinorelbine appears to be the
least expensive substance: its annual follow up costs 
per patient using specialised consultations every 3, 6, 
and 9 weeks were €6360, €6190, and €5940. The least
expensive regimen was the regimen involving entirely
home management following initial day hospitalisation:
€5940. IV cytotoxic agents administered in hospital: gem-
citabine, vinorelbine, docetaxel and paclitaxel had annual
follow up costs of 6970, €7400, €8320, and €9440
respectively. CONCLUSION: How can patient safety and
the will to keep a patient at home at the end of their life
be reconciled? An economic analysis can quantify the
ﬁnancial repercussions of the more or less extensive inter-
pretations which clinicians place on the principle of 
precaution.
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Capecitabine (Xeloda®) was the ﬁrst oral oncology drug
launched on the French market for the management of
metastatic colorectal cancer patients. This drug gives the
opportunity to caregivers to treat cancer on an outpatient
basis. OBJECTIVE: Assess the economic impact of
capecitabine compared with the FuFol/Mayo Clinic
chemotherapy regimen in metastatic colorectal cancer
from the French payer’s perspective. METHODS: A RCT
(SO 14796) demonstrated an equivalent efﬁcacy of the
two therapeutic strategies. Based on this clinical data, a
cost minimisation analysis was carried out. Costs were
assessed for hospitalisation, chemotherapy regimen
administration, management of adverse events and
patient monitoring. All these costs, with the exception 
